Navigation Links
Carl A. Miller, PhD, Joins iDiverse's Business and Scientific Advisory Board
Date:1/11/2011

DEL MAR, Calif., Jan. 12, 2011 /PRNewswire/ -- iDiverse today announced that Dr. Carl A. Miller has joined the company's Business and Scientific Advisory Board.

"We are extremely pleased to have Dr. Miller join our team at this time," said John Burr, president and CEO of iDiverse. "Dr. Miller has over forty years of extensive, hands on experience in the commercialization of novel bio-based technologies that have greatly improved the economics of production of biofuels and biomaterials. He has been directly involved in solving some of the very difficult problems associated with the pretreatment and fermentation of biomass materials to biofuels and chemicals. We believe our technology can play a significant role here and I am looking forward to Dr. Miller's help and support."

"I believe that iDiverse's technology will play an immediate role in overcoming many of the generally accepted limitations in the production of biofuels from a wide variety of fermentation substrates. The iDiverse technologies represent breakthroughs in the conventional paradigm of biofuel production from any feedstock but its greatest impact will be realized in the biomass-to-biofuels sector," said Dr. Miller.

Dr. Miller has an expansive background ranging from the development of cost-effective biofuel production process designs to the commercialization of novel industrial enzymes. He has held positions at Novozymes, Gist-brocades (now DSM), Diversa (now Verenium), Innovase and Syngenta, and is currently the president of Enventek, a biotechnology consulting company. Dr. Miller earned his PhD in bio-organic chemistry from Clemson University and did post-doctoral work on enzyme mechanism at Syracuse University.

About iDiverse

iDiverse, Inc. is a privately-held biotechnology company dedicated to developing and commercializing genetically enhanced cell lines for use in the bioproduction of fuel ethanol, industrial enzymes, and pharmaceuticals. It also pro
'/>"/>

SOURCE iDiverse, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Paul Pospisil Joins Korn/Ferry as Senior Client Partner in Biotechnology and Life Sciences Practice
2. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
3. Dr. Russell L. Chapman Joins Aquatic Energy as the Chairman of its Science Advisory Board
4. Dr. Michael Hanley Joins Celtaxsys as CEO
5. Edwin Rivera-Martinez, Former Chief of the FDA’s International Compliance Branch, Joins PAREXEL Consulting Strategic Compliance Team
6. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
7. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
8. Todd Park, Chief Technology Officer of U.S. Department of Health and Human Services, Joins Opening Keynote Line-Up at 2010 mHealth Summit
9. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
10. Excerpta Medica Joins Adelphi Worldwide
11. Philadelphia Eagles Offensive Lineman Todd Herremans Joins SPO Medical to Endorse New SPO Wellness(TM) Product Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... DuPont Pioneer announced today that Neal Gutterson, ... Agricultural Biotechnology (ABT), effective July 21, 2014. Gutterson joins ... as president, chief executive officer and board member. , ... seed and crop protection industry to this integral role ... president of DuPont Pioneer. “I am looking forward to ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... , July 23, 2014 ... SHPG ), the global specialty biopharmaceutical company, and ... announced a worldwide licensing and collaboration agreement for ... the potential treatment of both the central nervous ... Hunter syndrome (MPS II). This collaboration strengthens Shire,s ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a ... affordable vaccines based on proprietary manufacturing technologies and ... been awarded a proof of concept contract by ... laboratory specifically the Edgewood Chemical Biological Center ("ECBC") ...
... Guacamole is a little prettier in October as your ... "Pink" Guacamole. Nielsen-ranked, top-selling Wholly Guacamole, is for the ... proceeds from October "PINK" sales to help fight for ... of Texas-Based Wholly,s support for National Breast Cancer Awareness ...
... ... ... October 8, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core ... iCardiac a comprehensive cardiac safety study. iCardiac will provide end-to-end study management, equipment ...
Cached Biology Technology:Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy 2Grocery Produce Fighting for a Cause - Wholly 'Pink' Guacamole 2Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2
(Date:7/23/2014)... fatty acids and energy to infants and children ... that soybean-based emulsions could compromise immune functions and ... lipid emulsions based on triglyceride oil, fish oil, ... this concern. , However, researchers at Rutgers and ... according to a review published today in the ...
(Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
(Date:7/22/2014)... BEDFORD, Mass., July 22, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its second quarter ... quarter of 2014 was $6.8 million, an increase of 53% ... Operating income before patent related income in the second quarter ... the second quarter of 2013. The increase in revenue and ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... be taken during radiation therapy treatments because they ... normal prostate cell lines, leading to normal tissue ... issue of the International Journal of Radiation ... Society for Radiation Oncology (ASTRO). Many prostate cancer ...
... The Society for Nutrition Education (SNE) has ... American Society for Nutrition (ASN) to publish a ... American Society for Nutrition, and Society for Nutrition ... Adults," focusing on access to safe and adequate ...
... This release is available in Spanish . ... found in South America that can cause terrible, Ebola-like ... Now, Howard Hughes Medical Institute (HHMI) researchers ... hemorrhagic fever virus latches onto and infects human cells, ...
Cached Biology News:Dietary supplements discouraged for prostate cancer patients 2Nutrition services for older adults at home and in communities 2New ways to disarm deadly South American hemorrhagic fever viruses 2New ways to disarm deadly South American hemorrhagic fever viruses 3
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: